Fatigue Assessment Included in Simponi Aria Labeling
The prescribing information for the product has been updated to include this health related outcome.
The prescribing information for the product has been updated to include this health related outcome.
Given that treatment options for RA are rapidly changing, the study authors aimed to summarize information surrounding potential drug-drug interactions with JAK inhibitors in order to help health care providers make informed decisions.
WellDyne will provide physicians access to Scipher Medicine’s PrismRA test, which identifies RA patients unlikely to respond to TNFi therapy.
The randomized phase 3b/4 ORAL Surveillance study included 4362 RA patients who were taking methotrexate without adequate control of symptoms.
AVT02 is a proposed biosimilar to Humira® (adalimumab) with high concentration (100mg/mL) dosage forms.
RediTrex is approved for rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and psoriasis.
Researchers evaluated the safety and efficacy of switching between upadacitinib and adalimumab in patients with rheumatoid arthritis with nonresponse or incomplete response to initial therapy.
Risk for hospitalized infections up for patients with RA receiving DMARDs with continued glucocorticoid use
CL improved pain but did not change effusion-synovitis volume or cartilage composition.
RA treatment response does not appear to impact improvement in vascular stiffness.